Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

 
   By Saabira Chaudhuri 
 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
08/16 ELI LILLY AND : Kids Support Kids to Find Clinical Research Solutions
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second-q..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second q..
08/11 ELI LILLY AND COMPANY : ex-dividend day
08/10 ELI LILLY AND : New Ischemic Optic Neuropathy Findings from Eli Lilly and Compan..
08/10 ELI LILLY AND : Boehringer Ingelheim and Lilly to support new American College o..
08/10 ELI LILLY AND : Investigators from Eli Lilly and Company Target Medicinal Chemis..
08/10 ELI LILLY AND : Lilly Announces Positive Results for Second Phase 3 Study of Las..
08/10 ELI LILLY AND : Findings from Eli Lilly and Company in the Area of Hypoglycemia ..
08/09 ELI LILLY AND : Remembering Glen Campbell
More news
News from SeekingAlpha
08/16 Novo's semaglutide beats Lilly's dulaglutide in late-stage study in type 2 di..
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
08/14 A Portfolio Of Biotech Growth
08/11 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 11, 2017
08/09 GlaxoSmithKline Is Broker Pick As Top Dog For Healthcare Sector Gains In Augu..
Financials ($)
Sales 2017 22 494 M
EBIT 2017 5 579 M
Net income 2017 3 134 M
Debt 2017 5 911 M
Yield 2017 2,56%
P/E ratio 2017 31,47
P/E ratio 2018 20,04
EV / Sales 2017 4,26x
EV / Sales 2018 4,13x
Capitalization 89 962 M
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 90,0 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
Franklyn G. Prendergast Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY11.09%89 962
JOHNSON & JOHNSON15.77%357 992
NOVARTIS9.99%219 731
ROCHE HOLDING LTD.5.07%217 452
PFIZER2.77%198 782
MERCK AND COMPANY6.17%170 460